Tuesday, June 30, 2015 5:35:43 PM
https://career.loreal.com/careers/JobDetail/Sr-Scientist-Applied-Research-Skin-Transformation/6767
Job Function: Research
Employment type: Full - Time
Location: New Jersey - Clark
Country: USA
I. MAJOR FUNCTION
Identify new strategies to dramatically improve the appearance of the skin (targets such as: skin tone, dark spots, wrinkles) through the design of new technologies and prototype formulations which work alone or in synergistic associations with device.
Work in a team-oriented international environment (Instrumental Cosmetics, Applied Research, Advanced Research, and Development). Collaborate with various external groups.
II. PRINCIPAL ACCOUNTABILITIES
· Evaluate and characterize technologies and develop formulations containing those technologies which provide dramatic improvement to the skin surface / appearance in a quick and long-lasting manner.
· Develop evaluation screening methods on synthetic skin substrates or ex vivo skin to study the performance of the different technologies
· Work closely with Instrumental Cosmetics teams in France and Seattle, Regulatory, Safety and Evaluation to design the clinical trials.
· Maintain good knowledge of competitor’s patent environments and close awareness of consumer need gap and marketing trends.
· Put in place a patent strategy that will safeguard the technology and device
· Manage external collaborations as required
DESIRABLE TRAINING AND EXPERIENCE
· Ph.D. in Biomaterial Science, Biochemistry, Chemistry, Physical Chemistry, Surface science.
· Good knowledge of structure and property of biomaterials. Preferably with hands-on experience in dermatological/cosmetic industries with knowledge in skin/hair, and/or drug delivery or surface treatment.
· Ability to manage different projects in association with many teams (internal and external), design/perform in vitro/ex vivo experiments independently and deliver reliable data.
· Creative and self-motivated. Ability to think out of the box and willing to take an extra step to get the job done. Organized in experimental records and related documents.
· Excellent communication skills. Must be legally eligible to work in the US on an on-going basis
(extra spacing added for lack of actual content)
Recent ONVO News
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo • GlobeNewswire Inc. • 04/15/2024 12:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/09/2024 05:15:07 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/08/2024 09:56:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/08/2024 09:05:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:05:17 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/26/2024 10:09:03 PM
- Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress • GlobeNewswire Inc. • 01/25/2024 01:05:00 PM
- Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress • GlobeNewswire Inc. • 01/09/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:05:09 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/22/2023 11:05:02 AM
- Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results • GlobeNewswire Inc. • 12/06/2023 01:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/01/2023 09:07:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:41:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:40:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:37:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:34:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:32:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/15/2023 09:41:04 PM
- CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan • GlobeNewswire Inc. • 11/13/2023 01:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:10:34 PM
- Organovo Highlights FXR314 Combination Therapy Potential and Plan • GlobeNewswire Inc. • 11/08/2023 01:05:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 12:05:08 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 09/22/2023 08:05:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/13/2023 09:06:56 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM